Fermenta Biotech Ltd
Fermenta Biotech Q2 Results 2026 (FY27): Capex ₹60 Cr
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹133Cr
- Net profit
- ₹9Cr
- Margin
- 15.2%
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Fermenta Biotech Ltd Q2 FY27 key numbers
- Revenue
- Q2FY27 revenue was INR 135.8 crore, flat year-on-year (up 0.1% YoY) and up 8% quarter-on-quarter.
As stated in Fermenta Biotech Ltd's Q2 FY27 investor presentation · published 6 Nov 2026. Reported figures, not investment advice.
Based on Fermenta Biotech Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2FY27 revenue was INR 135.8 crore, flat year-on-year (up 0.1% YoY) and up 8% quarter-on-quarter (Page 5). Q2FY27 EBITDA: ₹23.2 crore, down 28% YoY, up 3% QoQ (Page 5).
From Fermenta Biotech Ltd's Q2 FY27 earnings-call transcript · updated 6 Nov 2026.
How did Fermenta Biotech's revenue grow in the September 2026 quarter?
- Q2FY27 revenue was INR 135.8 crore, flat year-on-year (up 0.1% YoY) and up 8% quarter-on-quarter (Page 5).
- Human Nutrition grew 2% in H1FY27 to INR 162.5 crore, with volumes up 7% over Q1 (Page 5).
- H1FY27 total income declined 7% YoY to INR 262 crore, impacted by animal nutrition price falls (Page 9).
- Animal nutrition revenue in H1FY27 dropped to INR 22 crore from INR 46 crore (down 52%) with volumes down 31% YoY and realizations down 35% YoY (Page 7).
2 more points from Fermenta Biotech Ltd's call on revenue
Create a free account to keep reading this call
What happened to Fermenta Biotech's margins in Q2 FY27?
See what Fermenta Biotech Ltd said on profitability & margins — free account, 30 seconds.
What capex is Fermenta Biotech planning?
- ₹60 crore capex for Dahej facility supporting commercial-scale production of VITADEE Green® plant-based Vitamin D3; capacity committed and funded (Pages 14, 15, 18).
- ₹110 crore Dahej capex approved in Dec 2025 for scaling up VITADEE Green® production (Page 15).
- VITADEE Green® capacity expected to be available from Q2FY28 (Page 5).
- Pilot plant and innovation hub for R&D and process development at Thane and Dahej (Page 14).
2 more points from Fermenta Biotech Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Fermenta Biotech raising money or cutting debt?
See what Fermenta Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Fermenta Biotech's order book?
See what Fermenta Biotech Ltd said on order book & pipeline — free account, 30 seconds.
Fermenta Biotech Ltd — Quarterly revenue & net profit
Fermenta Biotech Ltd Q2 FY27 results — key figures
| ₹ Cr | Q2 FY27 |
|---|---|
| Revenue | 133 |
| Operating profit (EBITDA) | 20 |
| Operating margin | 15.2% |
| Profit before tax | 14 |
| Net profit (PAT) | 9 |
| EPS (₹) | 3.40 |
Source: Fermenta Biotech Ltd's results filing to NSE (consolidated), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹133 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fermenta Biotech's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Divis Laboratories (Q2 FY27)
Consolidated total income: ₹3770 crores . Key results statement takeaways from Divis Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sec
- Infinium Pharma (Q2 FY27)
3,940.98 Lacs (about 54.3% increase) . Key results statement takeaways from Infinium Pharmachem Ltd's Q2 FY27 results statement — and how it ranks against secto
- Walpar Nutrition (Q2 FY27)
3,631.14 Lakhs for the half year ended September 30, 2025, reflecting a year-on-year increase of approximately 13.79%. Key results statement takeaways from Walp
- Kilitch Drugs (Q2 FY27)
14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fermenta Biotech Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fermenta Biotech Ltd Q2 FY27 results?
Q2FY27 revenue was INR 135.8 crore, flat year-on-year (up 0.1% YoY) and up 8% quarter-on-quarter (Page 5). Q2FY27 EBITDA: ₹23.2 crore, down 28% YoY, up 3% QoQ (Page 5).
What is Fermenta Biotech Ltd share price analysis?
Fermenta Biotech Ltd currently shows a neutral. The stock trades at a P/E of 24.0 with a market cap of ₹1,314 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fermenta Biotech Ltd planning capital expenditure?
₹60 crore capex for Dahej facility supporting commercial-scale production of VITADEE Green® plant-based Vitamin D3; capacity committed and funded (Pages 14, 15, 18).
Keep Fermenta Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.